Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases

Basit Öğe Kaydı
dc.authorwosidtsokos, george C/O-3360-2013
dc.contributor.authorPamuk, Omer N.
dc.contributor.authorTsokos, George C.
dc.date.accessioned2024-06-12T11:19:47Z
dc.date.available2024-06-12T11:19:47Z
dc.date.issued2010
dc.departmentTrakya Üniversitesien_US
dc.description.abstractSpleen tyrosine kinase (Syk) is involved in the development of the adaptive immune system and has been recognized as being important in the function of additional cell types, including platelets, phagocytes, fibroblasts, and osteoclasts, and in the generation of the inflammasome. Preclinical studies presented compelling evidence that Syk inhibition may have therapeutic value in the treatment of rheumatoid arthritis and other forms of arthritis, systemic lupus erythematosus, autoimmune cytopenias, and allergic and autoinflammatory diseases. In addition, Syk inhibition may have a place in limiting tissue injury associated with organ transplant and revascularization procedures. Clinical trials have documented exciting success in the treatment of patients with rheumatoid arthritis, autoimmune cytopenias, and allergic rhinitis. While the extent and severity of side effects appear to be limited so far, larger studies will unravel the risk involved with the clinical benefit.en_US
dc.description.sponsorshipGCT lab [PHS R01 AI42269]; DoD [W81XWH-09-1-0530]; Rigel Pharmaceuticals (South San Francisco, CA, USA); Scientific and Technological Research Council of Turkey (TUBITAK)en_US
dc.description.sponsorshipWork in the GCT lab was supported by PHS R01 AI42269, DoD W81XWH-09-1-0530, and a grant from Rigel Pharmaceuticals (South San Francisco, CA, USA). ONP was supported by a Scientific and Technological Research Council of Turkey (TUBITAK) scholarship.en_US
dc.identifier.doi10.1186/ar3198
dc.identifier.issn1478-6354
dc.identifier.issn1478-6362
dc.identifier.issue6en_US
dc.identifier.pmid21211067en_US
dc.identifier.scopus2-s2.0-79959261430en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1186/ar3198
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25340
dc.identifier.volume12en_US
dc.identifier.wosWOS:000287517000006en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBmcen_US
dc.relation.ispartofArthritis Research & Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectReceptor Gamma-Chainen_US
dc.subjectB-Cell Developmenten_US
dc.subjectSyk-Kinaseen_US
dc.subjectRheumatoid-Arthritisen_US
dc.subjectActivationen_US
dc.subjectInflammationen_US
dc.subjectPhagocytosisen_US
dc.subjectChallengeen_US
dc.subjectMechanismen_US
dc.subjectSymptomsen_US
dc.titleSpleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseasesen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu